Fortress Biotech, Inc 8-K, filed Jun 23, 2026
Fortress Biotech, Inc. (FBIO)
About this 8-K
Fortress Biotech, Inc filed this 8-K on June 23, 2026, reporting on events of June 17, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| |
| |
|
(Address of Principal Executive Offices)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform.
At the 2026 Annual Meeting, the following two proposals were voted on by the stockholders: (i) the election of seven directors to hold office until the 2027 annual meeting of stockholders or until such director resigns or is removed from office; and (ii) the ratification of the appointment of KPMG LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2026. The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 28, 2026.
Proposal 1
The votes with respect to the election of seven directors to hold office until the 2027 annual meeting of stockholders were as follows:
| | | | Total Votes | | | | Broker Non- |
Director | | Total Votes For | | Against | | Abstentions | | Votes |
Lindsay A. Rosenwald, M.D. |
| 11,022,326 | | 239,772 | | 32,188 | | 12,897,124 |
Jimmie Harvey, Jr., M.D. |
| 10,322,230 | | 923,184 | | 48,872 | | 12,897,124 |
Malcolm Hoenlein |
| 10,309,261 | | 932,328 | | 52,697 | | 12,897,124 |
Dov Klein, CPA |
| 10,323,030 | | 931,434 | | 39,822 | | 12,897,124 |
J. Jay Lobell | | 9,756,949 | | 1,313,658 | | 223,679 | | 12,897,124 |
Kevin L. Lorenz, J.D. | | 10,131,410 | | 939,137 | | 223,739 | | 12,897,124 |
Michael S. Weiss | | 10,961,271 | | 270,249 | | 62,766 | | 12,897,124 |
Proposal 2
The vote with respect to the ratification of the selection of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2026 was as follows:
Total Votes For | Total Votes Against | Abstentions |
23,095,864 | 753,612 | 341,934 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Fortress Biotech, Inc. | |
| (Registrant) | |
| | |
Date: June 23, 2026 | ||
| | |
| By: | /s/ David Jin |
|
| David Jin |
|
| Chief Financial Officer |